Cargando…

Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9

BACKGROUND: The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer therapies that block all ERK1/2 signaling may result in undesirable toxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Boston, Sarice R, Deshmukh, Rahul, Strome, Scott, Priyakumar, U Deva, MacKerell, Alexander D, Shapiro, Paul
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025971/
https://www.ncbi.nlm.nih.gov/pubmed/21219631
http://dx.doi.org/10.1186/1471-2407-11-7
_version_ 1782196976083795968
author Boston, Sarice R
Deshmukh, Rahul
Strome, Scott
Priyakumar, U Deva
MacKerell, Alexander D
Shapiro, Paul
author_facet Boston, Sarice R
Deshmukh, Rahul
Strome, Scott
Priyakumar, U Deva
MacKerell, Alexander D
Shapiro, Paul
author_sort Boston, Sarice R
collection PubMed
description BACKGROUND: The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer therapies that block all ERK1/2 signaling may result in undesirable toxicity to normal cells. As an alternative, we have used computational and biological approaches to identify low-molecular weight compounds that have the potential to interact with unique ERK1/2 docking sites and selectively inhibit interactions with substrates involved in promoting cell proliferation. METHODS: Colony formation and water soluble tetrazolium salt (WST) assays were used to determine the effects of test compounds on cell proliferation. Changes in phosphorylation and protein expression in response to test compound treatment were examined by immunoblotting and in vitro kinase assays. Apoptosis was determined with immunoblotting and caspase activity assays. RESULTS: In silico modeling was used to identify compounds that were structurally similar to a previously identified parent compound, called 76. From this screen, several compounds, termed 76.2, 76.3, and 76.4 sharing a common thiazolidinedione core with an aminoethyl side group, inhibited proliferation and induced apoptosis of HeLa cells. However, the active compounds were less effective in inhibiting proliferation or inducing apoptosis in non-transformed epithelial cells. Induction of HeLa cell apoptosis appeared to be through intrinsic mechanisms involving caspase-9 activation and decreased phosphorylation of the pro-apoptotic Bad protein. Cell-based and in vitro kinase assays indicated that compounds 76.3 and 76.4 directly inhibited ERK-mediated phosphorylation of caspase-9 and the p90Rsk-1 kinase, which phosphorylates and inhibits Bad, more effectively than the parent compound 76. Further examination of the test compound's mechanism of action showed little effects on related MAP kinases or other cell survival proteins. CONCLUSION: These findings support the identification of a class of ERK-targeted molecules that can induce apoptosis in transformed cells by inhibiting ERK-mediated phosphorylation and inactivation of pro-apoptotic proteins.
format Text
id pubmed-3025971
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30259712011-01-25 Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9 Boston, Sarice R Deshmukh, Rahul Strome, Scott Priyakumar, U Deva MacKerell, Alexander D Shapiro, Paul BMC Cancer Research Article BACKGROUND: The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer therapies that block all ERK1/2 signaling may result in undesirable toxicity to normal cells. As an alternative, we have used computational and biological approaches to identify low-molecular weight compounds that have the potential to interact with unique ERK1/2 docking sites and selectively inhibit interactions with substrates involved in promoting cell proliferation. METHODS: Colony formation and water soluble tetrazolium salt (WST) assays were used to determine the effects of test compounds on cell proliferation. Changes in phosphorylation and protein expression in response to test compound treatment were examined by immunoblotting and in vitro kinase assays. Apoptosis was determined with immunoblotting and caspase activity assays. RESULTS: In silico modeling was used to identify compounds that were structurally similar to a previously identified parent compound, called 76. From this screen, several compounds, termed 76.2, 76.3, and 76.4 sharing a common thiazolidinedione core with an aminoethyl side group, inhibited proliferation and induced apoptosis of HeLa cells. However, the active compounds were less effective in inhibiting proliferation or inducing apoptosis in non-transformed epithelial cells. Induction of HeLa cell apoptosis appeared to be through intrinsic mechanisms involving caspase-9 activation and decreased phosphorylation of the pro-apoptotic Bad protein. Cell-based and in vitro kinase assays indicated that compounds 76.3 and 76.4 directly inhibited ERK-mediated phosphorylation of caspase-9 and the p90Rsk-1 kinase, which phosphorylates and inhibits Bad, more effectively than the parent compound 76. Further examination of the test compound's mechanism of action showed little effects on related MAP kinases or other cell survival proteins. CONCLUSION: These findings support the identification of a class of ERK-targeted molecules that can induce apoptosis in transformed cells by inhibiting ERK-mediated phosphorylation and inactivation of pro-apoptotic proteins. BioMed Central 2011-01-10 /pmc/articles/PMC3025971/ /pubmed/21219631 http://dx.doi.org/10.1186/1471-2407-11-7 Text en Copyright ©2011 Boston et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Boston, Sarice R
Deshmukh, Rahul
Strome, Scott
Priyakumar, U Deva
MacKerell, Alexander D
Shapiro, Paul
Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_full Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_fullStr Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_full_unstemmed Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_short Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9
title_sort characterization of erk docking domain inhibitors that induce apoptosis by targeting rsk-1 and caspase-9
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025971/
https://www.ncbi.nlm.nih.gov/pubmed/21219631
http://dx.doi.org/10.1186/1471-2407-11-7
work_keys_str_mv AT bostonsaricer characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT deshmukhrahul characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT stromescott characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT priyakumarudeva characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT mackerellalexanderd characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9
AT shapiropaul characterizationoferkdockingdomaininhibitorsthatinduceapoptosisbytargetingrsk1andcaspase9